Tenax Therapeutics, Inc. (NASDAQ:TENX) Receives $37.67 Average Target Price from Analysts

by · The Markets Daily

Shares of Tenax Therapeutics, Inc. (NASDAQ:TENX – Get Free Report) have been given a consensus rating of “Moderate Buy” by the nine research firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, four have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $14.00.

Several equities analysts recently issued reports on TENX shares. Piper Sandler increased their target price on Tenax Therapeutics from $20.00 to $50.00 and gave the stock an “overweight” rating in a research note on Friday, June 12th. Evercore downgraded Tenax Therapeutics from an “outperform” rating to an “in-line” rating and set a $5.00 target price for the company. in a research report on Tuesday. Roth Capital set a $5.00 price target on shares of Tenax Therapeutics in a research note on Monday. Canaccord Genuity Group set a $4.00 price target on shares of Tenax Therapeutics and gave the stock a “buy” rating in a research report on Tuesday. Finally, Guggenheim set a $4.00 price objective on shares of Tenax Therapeutics and gave the company a “buy” rating in a research note on Tuesday.

Check Out Our Latest Research Report on Tenax Therapeutics

Tenax Therapeutics Price Performance

Shares of TENX stock opened at $1.72 on Monday. The firm’s 50-day moving average is $13.21 and its two-hundred day moving average is $13.19. Tenax Therapeutics has a 12 month low of $1.31 and a 12 month high of $19.40. The company has a market capitalization of $64.37 million, a PE ratio of -1.16 and a beta of 0.93.

Tenax Therapeutics (NASDAQ:TENX – Get Free Report) last issued its quarterly earnings data on Friday, July 31st. The specialty pharmaceutical company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.03. Sell-side analysts forecast that Tenax Therapeutics will post -1.44 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in TENX. Janus Henderson Group PLC increased its holdings in shares of Tenax Therapeutics by 989.3% in the 1st quarter. Janus Henderson Group PLC now owns 1,815,474 shares of the specialty pharmaceutical company’s stock valued at $29,066,000 after acquiring an additional 1,648,808 shares during the last quarter. Perceptive Advisors LLC lifted its stake in Tenax Therapeutics by 229.7% during the first quarter. Perceptive Advisors LLC now owns 1,447,782 shares of the specialty pharmaceutical company’s stock worth $23,150,000 after purchasing an additional 1,008,640 shares during the last quarter. Bank of New York Mellon Corp purchased a new stake in Tenax Therapeutics during the second quarter worth approximately $4,733,000. Diadema Partners LP purchased a new stake in Tenax Therapeutics during the fourth quarter worth approximately $2,964,000. Finally, Avidity Partners Management LP acquired a new position in Tenax Therapeutics in the first quarter valued at approximately $3,453,000. Institutional investors and hedge funds own 1.67% of the company’s stock.

About Tenax Therapeutics

(Get Free Report)

Tenax Therapeutics, Inc is a clinical-stage specialty pharmaceutical company developing drug delivery technologies designed to improve pain management in acute care settings. The company’s proprietary platform leverages biodegradable polymer matrices to create sustained-release formulations of local anesthetics, aiming to extend the duration of pain relief while reducing reliance on opioid medications.

Tenax’s lead development programs focus on injectable formulations intended for infiltration and peripheral nerve block applications, with the goal of providing longer-lasting analgesia following surgical and procedural interventions.

Featured Stories